Ampio Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock and Warrants
Published: Aug 09, 2018
ENGLEWOOD, Colo., Aug. 9, 2018 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) ("Ampio"), a clinical trial stage biopharmaceutical company primarily focused on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options, today announced the pricing of an underwritten public offering of 20,000,000 shares of its common stock and warrants to purchase up to 20,000,000 shares of common stock, at a combined purchase price of $0.40 per share of common stock and accompanying warrant, with anticipated gross proceeds of $8.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Ampio. The warrants are exercisable six months after issuance at a price of $0.40 per share of common stock and have a term of five years commencing six months after issuance. The offering is expected to close on or about August 13, 2018, subject to customary closing conditions.
All of the securities in the offering are to be sold by Ampio. Ampio intends to use the net proceeds from this offering for working capital and general corporate purposes, including continued preclinical development of Ampion and funding an Ampion clinical trial, if required.
Canaccord Genuity is acting as sole book-running manager for the offering.
The sale of the common stock and the accompanying warrants to purchase shares of common stock is being offered by Ampio pursuant to a shelf registration statement on Form S-3 (Registration No. 333-217094), which was declared effective by the Securities and Exchange Commission (the "SEC") on April 20, 2017. A final prospectus supplement relating to and describing the terms of the offering will be filed with the SEC, will be available on the SEC's website at www.sec.gov and will form a part of the effective registration statement. Copies of the final prospectus supplement and the accompanying prospectus relating to this offering may also be obtained, when available, by contacting Canaccord Genuity LLC, 99 High Street, Suite 1200, Boston, MA 02110, Attn: Syndicate Department, by telephone at (617) 371-3900 or by e-mail at firstname.lastname@example.org.
This press release does not and shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities law of any such state or jurisdiction.
About Ampio Pharmaceuticals:
Forward Looking Statements:
View original content with multimedia:http://www.prnewswire.com/news-releases/ampio-pharmaceuticals-inc-announces-pricing-of-public-offering-of-common-stock-and-warrants-300694734.html
SOURCE Ampio Pharmaceuticals, Inc.
Company Codes: AMEX:AMPE